Placebo News and Research

RSS
Calcium and vitamin D supplements can improve cholesterol profiles in postmenopausal women

Calcium and vitamin D supplements can improve cholesterol profiles in postmenopausal women

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Novel HIV prevention products for women demonstrate safety in clinical studies

Novel HIV prevention products for women demonstrate safety in clinical studies

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Randomized trial of bevacizumab for glioblastoma shows disappointing results

Randomized trial of bevacizumab for glioblastoma shows disappointing results

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Study reveals spinal manipulation therapy reduces severity of pain in many patients

Study reveals spinal manipulation therapy reduces severity of pain in many patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.